A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Patients with Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN (The Bloodwise / TAP PHAZAR Study on Behalf of the UK MPN CSG)

Mark W Drummond,Claire N Harrison,Samuel Munoz Vicente,Adam J Mead,Christina Yap,Frederick Chen,Srinivasan Narayanan,Dragana Milojkovic,Leyre Navarro-Nunez,Steven Knapper

doi:10.1182/blood.v130.suppl_1.1649.1649

A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Patients with Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN (The Bloodwise / TAP PHAZAR Study on Behalf of the UK MPN CSG)

Mark W Drummond, Claire N Harrison + Show 8 more

https://doi.org/10.1182/blood.v130.suppl_1.1649.1649

Copy DOI

Journal: Blood

Publication Date: Jun 25, 2021

Affiliation: Beatson West of Scotland Cancer Centre, Guy's and St Thomas' NHS Foundation Trust, Cancer Research UK Clinical Trials Unit, MRC Molecular Haematology Unit, University of Birmingham, Queen Elizabeth Hospital Birmingham, University Hospital Southampton NHS Foundation Trust, Imperial College Healthcare NHS Trust, Cardiff University

#Speakers Bureau #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Patients with Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN (The Bloodwise / TAP PHAZAR Study on Behalf of the UK MPN CSG)

Full Text